Sign in
Not yet taking people in United StatesPhase 1

A Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
22 people, planned
Started
Nov 2026
Expected to end
Dec 2031
Type of study
Interventional, 4 groups
Treatments tested
  • Mosunetuzumab
  • FHD-286
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Histologically confirmed diagnosis of FL
  • FL meeting criteria for initiation of systemic therapy per treating investigator and institutional standards
  • Eligible for SOC mosunetuzumab, which is currently FDA approved in FL after at least two prior lines of therapy
  • Age ≥ 18 years
  • ECOG performance status ≤ 2 (Appendix A)
  • Required initial laboratory parameters:, Hemoglobin ≥ 7 g/dL; transfusions permissible at treating physician discretion. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3. Platelet count ≥ 75,000 cells/mm3. Calculated creatinine clearance ≥ 45 ml/min by eGFR. Total bilirubin ≤ 1.5 x ULN. AST, ALT, and ALP ≤ 2.5 x ULN

Who cannot take part

  • Infection with HIV or hepatitis type B or C. Seropositive HBV patients are eligible if they are negative for HBV DNA by PCR and receive concomitant antiviral therapy during treatment and for additional six months after completion of therapy
  • Ongoing treatment with a moderate or strong CYP3A inhibitor. These include, but are not limited to medications as follows. An additional list of prohibited medications is listed in Appendix E
  • Major surgery within the preceding four months
  • Ongoing treatment with steroids equivalent to > 20mg prednisone daily
  • Active, uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
  • Active treatment or being within two years of active treatment for a second malignancy, excluding non-melanomatous skin cancer
  • Decompensated cardiac disease
  • History of allogeneic bone marrow transplant
  • Prolonged QTc interval, defined as a corrected QT interval (QTc) using Fridericia's formula (QTcF) > 470 msec
  • Known or suspected central nervous system (CNS) involvement by lymphoma
  • Any grade 3 or greater baseline AE
  • Life expectancy < 6 months
  • Evidence of transformation of FL
  • Active immunosuppression
  • Pregnant or breastfeeding

Where in United States

  • Weill Cornell MedicineNew York, United StatesContact: Simone Morris, RNNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if FHD-286 in combination with mosunetuzumab is safe and tolerable for treating adults with previously treated relapsed/refractory follicular lymphoma. It will also evaluate how well the combination works and how it affects cancer-related molecular and immune markers.The main questions it aims to answer are:

Read full original descriptionShow less

* What is the maximum tolerated dose of FHD-286 when given in combination with mosunetuzumab? * Is the combination of FHD-286 and mosunetuzumab safe and tolerable? * How many participants have a response to treatment, and how long does the treatment control the disease? * How does treatment affect circulating tumor DNA (ctDNA), immune responses, and molecular markers, including BAF complex mutational status?

Researchers will evaluate FHD-286 in combination with mosunetuzumab in participants with relapsed or refractory follicular lymphoma to assess safety, tolerability, and preliminary anti-tumor activity.

The 4 groups in the trial

  • Dose Level -1Treatment being tested

    2.5mg FHD-286 daily

    Treatment: Mosunetuzumab and FHD-286

  • Dose Level 0Treatment being tested

    5mg FHD-286 daily

    Treatment: Mosunetuzumab and FHD-286

  • Dose level +1Treatment being tested

    7.5mg FHD-286 daily

    Treatment: Mosunetuzumab and FHD-286

  • Dose Level +2Treatment being tested

    10mg FHD-286 daily

    Treatment: Mosunetuzumab and FHD-286

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Trial of FHD-286 Plus Mosunetuzumab in Previously Treated Follicular Lymphoma
Record updated
17 November 2026